-$0.45 Earnings Per Share Expected for Genocea Biosciences Inc (NASDAQ:GNCA) This Quarter

Equities research analysts predict that Genocea Biosciences Inc (NASDAQ:GNCA) will report earnings of ($0.45) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Genocea Biosciences’ earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.56). Genocea Biosciences reported earnings of ($0.72) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 37.5%. The business is expected to announce its next earnings results on Thursday, November 7th.

According to Zacks, analysts expect that Genocea Biosciences will report full-year earnings of ($2.36) per share for the current year, with EPS estimates ranging from ($2.77) to ($2.13). For the next financial year, analysts expect that the business will report earnings of ($1.64) per share, with EPS estimates ranging from ($1.87) to ($1.21). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, July 25th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.02).

A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Wednesday, July 3rd. HC Wainwright restated a “buy” rating and issued a $32.00 price target (down from $42.00) on shares of Genocea Biosciences in a research note on Thursday, July 25th. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Stifel Nicolaus assumed coverage on Genocea Biosciences in a research note on Monday, July 8th. They issued a “buy” rating for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $18.25.

Shares of GNCA stock traded down $0.03 during trading hours on Wednesday, hitting $3.07. 3,380 shares of the company were exchanged, compared to its average volume of 374,586. The stock has a market cap of $80.28 million, a price-to-earnings ratio of -0.83 and a beta of 2.40. Genocea Biosciences has a 1 year low of $2.24 and a 1 year high of $11.28. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.96 and a current ratio of 5.96. The business’s fifty day moving average price is $3.58.

In other news, major shareholder Peter W. Sonsini purchased 2,857,142 shares of the stock in a transaction on Monday, June 24th. The shares were acquired at an average price of $3.50 per share, for a total transaction of $9,999,997.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.33% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wedbush Securities Inc. acquired a new stake in Genocea Biosciences in the 2nd quarter worth approximately $43,000. Wells Fargo & Company MN raised its position in shares of Genocea Biosciences by 271.9% during the second quarter. Wells Fargo & Company MN now owns 33,631 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 24,587 shares during the period. DRW Securities LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $118,000. Monashee Investment Management LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $392,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $526,000.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Further Reading: Strike Price

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.